Invivyd says LIBERTY Phase 3 trial shows VYD2311 safety, tolerability top mRNA COVID-19 vaccine

By Public Technologies
  • Invivyd reported positive topline Phase 3 LIBERTY results for VYD2311, already released, showing better safety and tolerability than an mRNA COVID-19 vaccine.
  • Co-administration with an mRNA vaccine showed no sign of reducing vaccine-driven immune response, while increasing overall neutralizing activity.
  • The company plans to use LIBERTY with the ongoing DECLARATION pivotal study to support a U.S. BLA filing under FDA accelerated approval.
  • DECLARATION topline safety and immunogenicity results are expected in October, with clinical efficacy data planned to be unblinded post-approval if granted.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290701PRIMZONEFULLFEED9835498) on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.